PROM1 and glioblastoma: This radioimmunoconjugate demonstrated a maximum of 13%ID/g tumor uptake and minimum of 4%ID/g liver uptake (tumor/liver ratio = 3.25) at 6 days post-injection [13], which is exceeded by the tumor/liver ratio of 5.2 provided by [89Zr]-DFO(2.9)-RW03scFv − Fc at 168 h p.i. Other reports on antibody-based CD133 immunoPET utilize AC133.1 and other anti-CD133 targeted antibodies to show uptake and imaging of orthotopic PDX glioblastoma and PDX lung cancer mouse models, with tumor-to-off target uptake exceeding that provided by [89Zr]-DFO(2.9)-RW03scFv − Fc [14, 16].